Werewolf Therapeutics, Inc.

Werewolf Therapeutics' FY 2025 results reflect a company in a critical strategic transition, with operating and net losses narrowing to -$60.7M and -$60.8M, respectively, representing year-over-year improvements of 17.6% and 13.7%. This reduction in losses was primarily driven by a significant decrease in personnel costs, including lower discretionary bonuses and an overall reduction in headcount, as the company explores strategic alternatives to maximize stockholder value. The company's free cash flow was -$60.3M, with zero capital expenditures, indicating all cash burn is directed at sustaining operations rather than investing in future capacity. For investors, the narrative shifts from pure pipeline development to a high-stakes evaluation of strategic alternatives—including a potential sale, merger, or asset transaction—which will determine whether stockholder value can be realized from the PREDATOR platform and its early-stage oncology candidates, WTX-124 and WTX-330. Management's forward outlook is dominated by a strategic review process, with no defined timeline, creating significant uncertainty around future funding requirements and development plans.

Key Takeaways